Clinical Trial Update: Phase 2 Clinical Proof-of-Concept Study of the Cardioprotective Properties of Danegaptide in ST Segment Elevation Myocardial Infarction [Phase 2]

View source ↗

Summary

Phase 2 proof-of-concept trial evaluating the cardioprotective effects of danegaptide in ST-elevation myocardial infarction has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• St-elevation Myocardial Infarction

Drugs mentioned

• Danegaptide (danegaptide)

Snippet

Sponsor: Zealand Pharma | Conditions: Focus of Study is STEMI | Phase 2 | Status: COMPLETED